Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results
Biofrontera AG (NASDAQ: BFRA) will announce its financial results for the first half of 2020 on August 26, 2020. A conference call for shareholders is scheduled for August 27, 2020, with sessions in German at 10:00 am CEST and in English at 2:00 pm CEST. Investors can participate by dialing the provided numbers. This event is crucial for stakeholders to assess the company's financial performance and future outlook.
- Company is preparing to release its financial results which may provide insights into potential growth.
- Conference calls scheduled for August 27, 2020, allow direct engagement with shareholders.
- None.
Leverkusen, Germany, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2020 on Wednesday, August 26, 2020.
Conference calls for shareholders and interested investors will be held on Thursday, August 27, 2020, at the following times:
In German, August 27, 2020 at 10:00 am CEST (4:00 am EST)
Dial-in number Germany: +49 69201744220
Conference code: 43177738#
In English, August 27, 2020 at 2:00 pm CEST (8:00 am EST)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 41610190#
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
-End-
| For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer | +49 (0) 214 87 63 2 0 ir@biofrontera.com |
| IR UK: Seton Services Toni Vallen | +44 (0) 207 229 0805 |
About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
FAQ
When will Biofrontera AG release its financial results for the first half of 2020?
What times are the conference calls for Biofrontera AG scheduled?
How can I participate in Biofrontera AG’s conference calls?
What is Biofrontera AG's stock symbol?
